The Campbell Analysis: Deconstructing Cullinan’s Bispecific Gambit at ASH 2026

CAMBRIDGE, Mass. – November 4, 2026 – For years, the biopharmaceutical industry has treated acute myeloid leukemia (AML) as the graveyard of immunotherapies. While T cell redirection strategies have revolutionized the treatment of B-cell malignancies, the sheer heterogeneity of myeloid leukemias—and the dangerous overlap of target antigens on healthy stem cells—has kept sustained breakthroughs frustratingly out of reach. But when Cullinan Therapeutics announced its lineup for the 68th American Society of Hematology (ASH) Annual Meeting this morning, the underlying signal was clear: the Cambridge-based biotech believes it has finally engineered a way around the barricades.

The company confirmed that four poster presentations detailing its T cell engager programs, CLN-049 and velinotamig, will be featured in New Orleans this December. On the surface, it is a standard clinical update. But reading the intent behind the data reveals a broader strategic evolution. Cullinan is aggressively positioning itself at the intersection of two of the industry’s most lucrative frontiers: cracking the code on hard-to-treat hematologic cancers and repurposing oncology modalities for severe autoimmune diseases.

Cracking the AML Toxicity Barrier

The most closely watched data at ASH will undoubtedly be the updated Phase 1 dose-escalation results for CLN-049, an investigational FLT3xCD3 bispecific T cell engager targeting relapsed or refractory AML and myelodysplastic syndrome (MDS).

Historically, the challenge with deploying T cell engagers in AML has not been a lack of efficacy, but a surplus of toxicity. Activating a patient’s immune system to attack myeloid blasts frequently triggers severe cytokine release syndrome (CRS), forcing clinicians to halt treatment before it can eradicate the cancer. Cullinan’s approach with CLN-049 is fundamentally an exercise in risk mitigation and target expansion. Unlike existing FLT3 inhibitors such as gilteritinib or midostaurin, which primarily target mutated forms of the receptor, CLN-049 is designed to bind to both mutated and wild-type FLT3. Given that FLT3 is expressed on leukemic blasts in over 80% of patients, this structural choice significantly widens the drug's total addressable market.

But the true forensic detail lies in the dosing schedule. According to the data released ahead of the conference, Cullinan implemented a double step-up dosing regimen that successfully suppressed the immune system's most violent reactions. By introducing the drug in carefully escalated increments before hitting the target Phase 2 doses of 6 µg/kg and 12 µg/kg, the incidence of CRS dropped from 36% to 26%, with zero Grade 3 or higher CRS events reported in the two-step-up group.

This is the precise signal institutional investors have been waiting for. Efficacy is irrelevant if the safety profile precludes widespread clinical adoption. At the 12 µg/kg target dose, the overall response rate (ORR) hit 45%, with a composite complete response (CRc) rate of 21%. Even more striking is the drug's performance in patients with TP53-mutated AML—a demographic with notoriously dismal prognoses—where earlier data cuts showed half of the patients achieving a response. Armed with Fast Track and Orphan Drug designations from the U.S. FDA, Cullinan is now preparing to transition CLN-049 into a potentially registrational Phase 2 study in the third quarter of 2026.

The Autoimmune Pivot: Engineering Out the Storm

While CLN-049 anchors the oncology narrative, Cullinan’s second focus at ASH highlights a massive paradigm shift currently sweeping the biotech sector: the deployment of targeted cellular therapies against autoimmune diseases.

Velinotamig (CLN-803) is a BCMAxCD3 bispecific T cell engager. While BCMA has been thoroughly validated as a target in multiple myeloma, Cullinan is directing velinotamig at immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Both are rare, heterogeneous autoimmune conditions driven by pathogenic, autoantibody-producing plasma cells that prematurely destroy platelets and red blood cells, respectively.

The strategic intent behind velinotamig is heavily reliant on its molecular architecture. The drug is engineered with a high affinity for BCMA to aggressively hunt down pathogenic B-lineage cells, combined with a lower affinity for CD3. This intentional mismatch is designed to deplete the problematic plasma cells without triggering the massive, non-specific T cell activation that leads to cytokine-related toxicity.

Cullinan did not discover velinotamig in-house. In a calculated maneuver in June 2025, the company licensed the asset globally (excluding Greater China) from Genrix Bio for $20 million upfront and up to $692 million in potential milestones. Industry observers point out that this licensing deal allowed Cullinan to instantly leapfrog into the autoimmune space, leveraging prior oncology data generated by Genrix to accelerate global Phase 1b/2a trials.

Preclinical data slated for ASH will confirm velinotamig's selective targeting capabilities, while a Trials in Progress poster will outline the blueprint for its global clinical evaluation. If successful, this approach could offer a functional cure for patients who currently cycle through transient therapies that merely manage symptoms rather than eliminating the disease's cellular root.

A Dual-Front Strategic Evolution

To understand the significance of these ASH presentations, one must look at Cullinan's balance sheet and broader pipeline. The company is actively shedding its identity as an early-stage platform biotech, maturing into a clinical-stage leader with multiple shots on goal.

Financially, the company is operating from a position of profound strength. Reporting $356.0 million in cash and investments as of mid-2026, management has secured a runway that stretches into 2029. This capital efficiency provides the breathing room necessary to execute complex, global clinical trials without the immediate threat of dilutive financing hanging over their share price.

Furthermore, the bispecific pipeline is fundamentally derisked by the impending maturity of zipalertinib, a targeted oncology asset partnered with Taiho Oncology. With a New Drug Application currently under FDA review for second-line EGFR ex20ins non-small cell lung cancer (NSCLC) and a PDUFA date set for February 2027, zipalertinib could soon provide a commercial revenue stream. This impending commercialization bridge allows Cullinan to aggressively pursue high-reward, high-risk assets like CLN-049 and velinotamig without betting the entire company on a single binary readout.

The Outlook for New Orleans

The narrative Cullinan brings to ASH 2026 is one of calculated ambition. By showcasing monotherapy efficacy and manageable safety in heavily pretreated AML, while simultaneously advancing a combination trial of CLN-049 with azacitidine and venetoclax in newly diagnosed patients, the company is signaling its intent to challenge the standard of care across the entire leukemia treatment paradigm.

Simultaneously, the velinotamig presentations serve as a stake in the ground for the company’s immunology franchise, proving that the tools forged in the fires of oncology can be precisely calibrated to reset the immune system in autoantibody-driven diseases.

Ultimately, the data presented in December will serve as a litmus test for the broader biopharma industry's shift toward engineered bispecifics. As the hematology community converges on New Orleans, the true measure of Cullinan’s success will not just be found in the response rates, but in whether they have permanently rewritten the rules of engagement for T cell redirection therapies.